Please login to the form below

Not currently logged in
Email:
Password:

Efient

This page shows the latest Efient news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Efient and Sucampo's Amitiza win NICE backing

Lilly’s Efient and Sucampo's Amitiza win NICE backing

New Efient guidance. NICE also updated the guidance for blood clot prevention drug Efient to include a wider reach of patients. ... This expands Efient's use beyond its 2009 recommendation for use in combination with aspirin as an option for preventing

Latest news

  • Coronary conundrums

    Eli Lilly's prasugrel (Effient, Efient and Prasita) is an antiplatelet that represents an advance over clopidogrel, with more potent and consistent inhibition of the same P2Y12 receptor.

  • Straight from the heart

    Efient (Daiichi Sankyo/Lilly). 16%. 3. Pradaxa (Boehringer Ingelheim). 13%. 4=. Angiox (Nycomed). ... Efient, another recent launch, may be the most likely to have used an educational meeting strategy.

  • Close but no cigar

    Argentina, Mexico. Prasugrel. Efient (Daiichi Sankyo, Eli Lilly). Acute coronary syndromes.

  • Antiplatelet heart drug launched

    UK patients are the first to benefit from new heart drug, prasugrel (Efient), following authorisation by the European Medicines Agency.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Milestone names chief medical officer Milestone names chief medical officer

    His other big pharma experience includes roles at Daiichi-Sankyo, Novartis, and Bristol Myers Squibb, working on cardiovascular products including Efient, Diovan and Approvel.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...
MIT reveals new pill to deliver insulin
A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...

Infographics